Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) have received a consensus rating of “Moderate Buy” from the six research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $37.3333.

A number of analysts have recently weighed in on the company. TD Cowen reaffirmed a “buy” rating on shares of Nanobiotix in a research report on Thursday, March 12th. Guggenheim upped their price objective on Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, April 2nd. HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a research report on Monday, May 18th. Leerink Partners upped their price objective on Nanobiotix from $37.00 to $46.00 and gave the stock an “outperform” rating in a research report on Thursday, June 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a research report on Tuesday, April 21st.

Nanobiotix Price Performance

Nanobiotix stock opened at $36.27 on Friday. Nanobiotix has a twelve month low of $4.31 and a twelve month high of $57.14. The stock’s fifty day simple moving average is $38.14 and its 200-day simple moving average is $29.95.

Nanobiotix (NASDAQ:NBTX) last posted its quarterly earnings data on Sunday, February 15th. The company reported ($0.23) earnings per share for the quarter. The firm had revenue of $3.42 million during the quarter. On average, analysts predict that Nanobiotix will post 0.19 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Nanobiotix

Several large investors have recently bought and sold shares of NBTX. Royal Bank of Canada increased its holdings in Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares during the last quarter. Optiver Holding B.V. purchased a new position in Nanobiotix in the third quarter valued at $101,000. Marshall Wace LLP purchased a new position in Nanobiotix in the fourth quarter valued at $220,000. Finally, Millennium Management LLC purchased a new position in Nanobiotix in the fourth quarter valued at $390,000. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.